tbuckley/cabot-search huggingface dataset:
Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial
Authors: B-Ole Juhnke, Marco Gessi, Nicolas U Gerber, Carsten Friedrich, Martin Mynarek, André O von Bueren, Christine Haberler, Ulrich Schüller, Rolf-Dieter Kortmann, Beate Timmermann, Brigitte Bison, Monika Warmuth-Metz, Robert Kwiecien, Stefan M Pfister, Claudia Spix, Torsten Pietsch, Marcel Kool, Stefan Rutkowski, Katja von Hoff
Journal: Neuro-Oncology (2021)

Abstract Background Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry. Patients and methods Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry (2012-2014; n = 12), and earlier HIT trials (n = 4) were selected for analysis. Results Age-adjusted incidence rate was 1.35 per 1 million children (aged 1-4 years) in the years 2012-2014. Median age at diagnosis for 35 patients was 2.9 years. Metastases at diagnosis were detected in 9 patients. One patient died due to postoperative complications. For 30 patients with non-brainstem tumor location, 5-year progression-free survival (PFS) and overall survival (OS) were 35% and 47% after treatment with CARBO/ETO + HDCT (n = 17), compared to 0% and 8% with other treatments (n = 13, P[OS] = .011). All 4 patients with brainstem tumor died within 10 months after diagnosis. By multivariable analysis, supratentorial location: (HR [PFS]: 0.07 [95%CI: 0.01-0.38], P = .003), localized disease (M0): (HR [OS] M0, no residual tumor: 0.30 [95%CI: 0.009-1.09], P = .068; M0, residual tumor: 0.18 [95%CI: 0.04-0.76], P = .020), and CARBO/ETO + HDCT treatment (HR [OS]: 0.16 [95%CI: 0.05-054], P = .003) were identified as independent prognostic factors. Of 9 survivors, 6 were treated with radiotherapy (craniospinal 4; local 2). Conclusions Our data indicate improved survival with intensified chemotherapy (CARBO/ETO + HDCT). However, despite intensive treatment, the outcome was poor. Thus, innovative therapies need to be evaluated urgently in an upfront setting.
OUTCOMES OF LIFE-THREATENING CARDIOVASCULAR COMPLICATIONS AND CORONAVIRUS DISEASE 19- A COHORT STUDY
Authors: Michael Khorsandi, Nirmala Manjappachar, Adrien Mazer, Mitchell Karpman, Jennifer Grover, Joseph L. Nates, Dereddi Raja Reddy, Nargiz Muganlinskaya
Journal: Journal of the American College of Cardiology (2021)
RISING PREVALENCE OF OBESE HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE UNITED STATES
Authors: Varun Sundaram, Salil Deo, Mariam Rana, Padmini Selvaganesan, Joseph Rubelowsky, Yakov Elgudin, Sri Krishna Madan Mohan, Richard Josephson, Jayakumar Sahadevan, Yogesh Reddy
Journal: Journal of the American College of Cardiology (2021)
IMPACT OF ALZHEIMER'S ON IN-HOSPITAL OUTCOMES OF PATIENTS ADMITTED WITH ATRIAL FIBRILLATION- ANALYSIS OF NATIONAL INPATIENT SAMPLE
Authors: Mukunthan Murthi, Sujitha Velagapudi, Ramtej Atluri, Genaro Velazquez, Abdul Wahab Arif, Hafeez Shaka
Journal: Journal of the American College of Cardiology (2021)
Covid-19: MHRA is concerned over use of rapid lateral flow devices for mass testing
Authors: Gareth Iacobucci
Journal: BMJ (2021)

Previous studies have demonstrated that when we observe somebody else executing an action many areas of our own motor systems are active. It has been argued that these motor activations are evidence that we motorically simulate observed actions; this motoric simulation may support various functions such as imitation and action understanding. However, whether motoric simulation is indeed the function of motor activations during action observation is controversial, due to inconsistency in findings. Previous studies have demonstrated dynamic modulations in motor activity when we execute actions. Therefore, if we do motorically simulate observed actions, our motor systems should also be modulated dynamically, and in a corresponding fashion, during action observation. Using magnetoencephalography, we recorded the cortical activity of human participants while they observed actions performed by another person. Here, we show that activity in the human motor system is indeed modulated dynamically during action observation. The finding that activity in the motor system is modulated dynamically when observing actions can explain why studies of action observation using functional magnetic resonance imaging have reported conflicting results, and is consistent with the hypothesis that we motorically simulate observed actions.
SEX DIFFERENCES IN HEART FAILURE OUTCOMES ARE NOT ACCOUNTED BY AGE, CO-MORBIDITIES OR ACCESS TO CARE AFTER ACUTE MYOCARDIAL INFARCTION
Authors: Perman Pandal, Kwame Bodor-Tsia Atsina, Eliseo Vazquez, Elizabeth Cortez-Toledo, Alejandra Galina Bernal Fausto, Stephen Immanuel Warren, Shadi Nicole Nemanpour, Daniel Hogan Slack, Javier E. López
Journal: Journal of the American College of Cardiology (2021)
CORRELATION OF ELECTROCARDIOGRAPHIC RHYTHM INTERPRETATIONS IN KNOWN ATRIAL FIBRILLATION OR ATRIAL FLUTTER PATIENTS USING THE APPLE WATCH
Authors: Nabeel Saghir, Arjun Aggarwal, Nisha Soneji, David Ben-Nun, Hanna Fanous, Samuel Kessel, George Rodgers, Kristopher Heinzman, Mauricio Hong, Thomas Kurian
Journal: Journal of the American College of Cardiology (2021)
Enormously dilated pancreatic duct
Authors: Ronald Koschny, Matthias Lang, Thilo Hackert
Journal: Gut (2021)

A diabetic patient presented with 10 kg weight loss and slightly elevated C reactive protein without diarrhoea, abdominal pain, fever or leucocytosis. Serum lipase, transaminases, bilirubin, carcinoembryonic antigen and CA19-9 were normal. Ultrasound showed prominent perihilar bile ducts and a cystic mass of the pancreas (60×57 mm) with echogenic internal structures, which was identified as the main pancreatic duct on endoscopic ultrasound (EUS), without enlarged peripancreatic lymph nodes (figure 1A,B). At endoscopic retrograde cholangio-pancreatography (ERCP), the compressed common bile duct was secured by a plastic stent. Cannulation of the pancreatic duct resulted in massive putrid secretion and confirmed an enormously dilated main pancreatic duct over its full length (figure 1C,D).



Figure 1 
(A) …
IMPROVEMENT OF LEFT VENTRICULAR EJECTION FRACTION IN PATIENTS WITH ACUTE HEART FAILURE
Authors: Kodchakorn Theanvarich, Koravich Lorlowhakarn, Chayudtad Tanathaipakdee, Thanaporn Ratchataswan, Suchapa Arayakarnkul, Thiratest Leesutipornchai, Aekarach Ariyachaipanich
Journal: Journal of the American College of Cardiology (2021)
THE ASSOCIATION BETWEEN CARDIOVASCULAR MULTIMORBIDITY AND SHORT-TERM SYMPTOM IMPROVEMENT AFTER PERCUTANEOUS CORONARY INTERVENTION FOR STABLE ANGINA
Authors: Christopher Flynn, Ariela Orkaby, Parag Goyal, Linda Valsdottir, Daniel Kramer, Kalon K. Ho, John Dodson, Robert Yeh, Jordan Strom
Journal: Journal of the American College of Cardiology (2021)
MITRACLIP AS A SALVAGE SOLUTION FOR REFRACTORY CARDIOGENIC SHOCK AND RESPIRATORY FAILURE DUE TO ACUTE SEVERE MITRAL REGURGITATION IN THE SETTING OF A SMALL TETHERED POSTERIOR LEAFLET
Authors: Miranda Merrill, Kris Kumar, Harsh Golwala, Firas Zahr, Joaquin Cigarroa, Joshua Vogt, Howard K. Song, Scott M. Chadderdon
Journal: Journal of the American College of Cardiology (2021)
Abstract 10827: Growth Differentiation Factor 15 and Mortality in Prediabetic Patients With Suspected or Known Coronary Artery Disease: From the ANOX Study
Authors: Hiromichi Wada, Masahiro Suzuki, Morihiro Matsuda, Yoichi Ajiro, Tsuyoshi Shinozaki, Satoru Sakagami, Kazuya Yonezawa, Masatoshi Shimizu, Junichi Funada, Takashi Takenaka, Yukiko Morita, Toshihiro Nakamura, Kazuteru Fujimoto, Hiromi Matsubara, Toru Kato, Takashi Unoki, Daisuke Takagi, Kyohma Wada, Miyaka Wada, Moritake Iguchi, Nobutoyo Masunaga, Mitsuru Ishii, Kazuhiko Kotani, Mitsuru Abe, Masaharu Akao, Koji Hasegawa
Journal: Circulation (2019)

Background: Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine that plays an important role in the regulation of the inflammatory response, growth and cell differentiation. A...
UTILIZING XSPECT/CT DERIVED STANDARDIZED UPTAKE VALUES TO BETTER QUANTIFY DISEASE BURDEN IN PATIENTS WITH TRANSTHYRETIN-RELATED AMYLOIDOSIS
Authors: Juan Carlo Avalon, Jacob Fuqua, Seth Deskins, Tyler Miller, Daniel Martin, Gary Marano, James Mills, Christopher Bianco, Yasmin Hamirani
Journal: Journal of the American College of Cardiology (2021)
CLINICAL IMPACT OF NON-HDL-C ASSESSMENT TO PREDICT OCCURRENCE OF NEW LESIONS AFTER PERCUTANEOUS CORONARY INTERVENTION IN STABLE ANGINA PATIENTS PRESCRIBED STATINS
Authors: Daisuke Kanda, Masaaki Miyata, Kazuhiro Anzaki, Ryo Arikawa, Takeshi Sonoda, Akihiro Tokushige, Yoshiyuki Ikeda, Mitsuru Ohishi
Journal: Journal of the American College of Cardiology (2021)
CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration
Authors: Linda Kwakkenbos, Mahrukh Imran, Stephen J McCall, Kimberly A McCord, Ole Fröbert, Lars G Hemkens, Merrick Zwarenstein, Clare Relton, Danielle B Rice, Sinéad M Langan, Eric I Benchimol, Lehana Thabane, Marion K Campbell, Margaret Sampson, David Erlinge, Helena M Verkooijen, David Moher, Isabelle Boutron, Philippe Ravaud, Jon Nicholl, Rudolf Uher, Maureen Sauvé, John Fletcher, David Torgerson, Chris Gale, Edmund Juszczak, Brett D Thombs
Journal: BMJ (2021)

Randomised controlled trials are increasingly conducted as embedded, nested, or using cohorts or routinely collected data, including registries, electronic health records, and administrative databases, to assess if participants are eligible for the trial and to facilitate recruitment, to deliver an embedded intervention, to collect trial outcome data, or a combination of these purposes. This report presents the Consolidated Standards of Reporting Trials (CONSORT) extension for randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE). The extension was developed to look at the unique characteristics of trials conducted with these types of data with the goal of improving reporting quality in the long term by setting standards early in the process of uptake of these trial designs. The extension was developed with a sequential approach, including a Delphi survey, a consensus meeting, and piloting of the checklist. The checklist was informed by the CONSORT 2010 statement and two reporting guidelines for observational studies, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement and the REporting of studies Conducted using Observational Routinely collected Data (RECORD) statement. The extension includes eight items modified from the CONSORT 2010 statement and five new items. Reporting items with explanations and examples are provided, including key aspects of trials conducted using cohorts or routinely collected data that require specific reporting considerations.
ANOMALOUS RIGHT CORONARY ARTERY FROM THE LEFT SINUS OF VALSALVA WITH AN INTERARTERIAL COURSE: OUTCOME IN ADULTS MANAGED WITHOUT INTERVENTION
Authors: Eric Warner, Aishwarya Gulati, Ethan Halpern, David Fischman, Nicholas Ruggiero, Melissa McCarey, Michael Savage
Journal: Journal of the American College of Cardiology (2021)
Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination
Authors: Federico Martinón-Torres, Angelika Banzhoff, Chiara Azzari, Philippe De Wals, Robin Marlow, Helen Marshall, Mariagrazia Pizza, Rino Rappuoli, Rafik Bekkat-Berkani
Journal: Journal of Infection (2021)

4CMenB is a broadly protective vaccine against invasive meningococcal capsular group B disease (MenB IMD). Licensed worldwide based on immunogenicity and safety data, effectiveness and impact data are now available. We comprehensively reviewed all available real-world evidence gathered from use of 4CMenB since licensure.Data from 7 countries provide evidence of effectiveness and impact across different healthcare settings and age-groups, including national/regional immunization programs, observational studies and outbreak control. At least 2 4CMenB doses reduced MenB IMD by 50%-100% in 2-month to 20-year-olds depending on length of follow-up. Estimates of vaccine effectiveness in fully vaccinated cohorts ranged from 59%-100%. The safety profile of 4CMenB administered in real-world settings was consistent with pre-licensure clinical trial data.MenB IMD is an uncommon but life-threatening disease with unpredictable epidemiology. The substantial body of data demonstrating 4CMenB effectiveness and impact supports its use in IMD prevention. The results reinforce the importance of direct protection of the highest risk groups; infants/young children and adolescents. Direct protection via routine infant immunization with catch-up in young children and routine adolescent vaccination could be the preferred option for MenB disease control. A Video Abstract linked to this article is available on Figshare: https://doi.org/10.6084/m9.figshare.14546790.
LACK OF MYOCARDIAL INJURY AFTER MAGNETIC RESONANCE IMAGING IN PATIENTS WITH CONDITIONAL AND NON-CONDITIONAL CARDIAC IMPLANTABLE ELECTRONIC DEVICES -A HIGH SENSITIVITY TROPONIN EVALUATION
Authors: Ronstan Lobo, Heidi A. Edmonson, Leslie Donato, Paul Friedman, Amy M. Wockenfus, Yong-Mei Cha, Kiaran P. McGee, Joel P. Felmlee, Robert Watson, Allan Jaffe
Journal: Journal of the American College of Cardiology (2021)
THE PROGNOSTIC ROLE OF SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AMONG OLDER ADULTS: ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY
Authors: Ali Agha, Aliza Hussain, Amil Shah, Ron Hoogeveen, Carol Sun, Salim Virani, Vijay Nambi, Bing Yu, Elizabeth Selvin, Kunihiro Matsushita, Leo Buckley, Lin Chen, Pranav Dorbala, Christie Ballantyne
Journal: Journal of the American College of Cardiology (2021)
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
Authors: Nancy U. Lin, Mark Pegram, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney Kirschbrown, Priya Kumthekar
Journal: Journal of Clinical Oncology (2021)

Effective therapies are needed for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with brain metastases. A trastuzumab radioisotope has been shown to localize in brain metastases of patients with HER2-positive MBC, and intracranial xenograft models have demonstrated a dose-dependent response to trastuzumab.
Current and future treatment strategies in chronic lymphocytic leukemia
Authors: Krish Patel, John M. Pagel
Journal: Journal of Hematology & Oncology (2021)

Abstract Treatment decisions for patients with chronic lymphocytic leukemia (CLL) are dependent on symptoms and classification into high-, medium-, or low-risk categories. The prognosis for CLL hinges, in part, on the presence or absence of less-favorable genetic aberrations, including del(17p), del(11q), TP53 dysfunction, and IGHV mutations, as these markers are associated with worse treatment response. Promising results from multiple clinical trials show emerging therapies targeting Burton tyrosine kinase, B-cell leukemia/lymphoma 2, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta result in better outcomes and prolonged progression-free survival for patients both with and without certain high-risk aberrations. Favorable outcomes using these novel oral targeted therapies, either alone or in combination with other treatments such as anti-CD20 antibodies, has led to their use almost entirely supplanting chemoimmunotherapy in the treatment of CLL. In this narrative review, we summarize the current clinical evidence for the use of targeted mono- and combination therapies for CLL, discuss new and next-generation treatment approaches currently in development, and provide insight into areas of unmet need for the treatment of patients with CLL.
Platelet MHC class I mediates CD8+ T-cell suppression during sepsis
Authors: Li Guo, Sikui Shen, Jesse W. Rowley, Neal D. Tolley, Wenwen Jia, Bhanu Kanth Manne, Kyra N. McComas, Ben Bolingbroke, Yasuhiro Kosaka, Krystin Krauel, Frederik Denorme, Shancy P. Jacob, Alicia S. Eustes, Robert A. Campbell, Elizabeth A. Middleton, Xiao He, Samuel M. Brown, Craig N. Morrell, Andrew S. Weyrich, Matthew T. Rondina
Journal: Blood (2021)
FIVE-YEAR IMPLEMENTATION OF A COMPREHENSIVE ST-ELEVATION MYOCARDIAL INFARCTION PROTOCOL LEADS TO SUSTAINED IMPROVEMENTS IN DOOR-TO-BALLOON TIME, IN-HOSPITAL MORTALITY RATE, AND BLEEDING COMPLICATION RATE
Authors: Weili Zheng, Chetan Huded, Anirudh Kumar, Michael Johnson, Kathleen Kravitz, Grant Reed, Amar Krishnaswamy, A. Lincoff, Stephen W. Meldon, Kralovic M. Damon, Samir Kapadia, Umesh Khot
Journal: Journal of the American College of Cardiology (2021)
頻繁なPVT1転位と新規キメラ遺伝子PVT1-NBEAおよびPVT1-WWOXは,8q24異常を伴う多発性骨髄腫において発生する
Authors: Nagoshi Hisao, Taki Tomohiko, Hanamura Ichiro, Nitta Masakazu, Otsuki Takemi, Nishida Kazuhiro, Okuda Keiko, Sakamoto Natsumi, Kobayashi Satoru, Yamamoto-Sugitani Mio, Tsutsumi Yasuhiko, Kobayashi Tsutomu, Matsumoto Yosuke, Horiike Shigeo, Kuroda Junya, Taniwaki Masafumi
Journal: Cancer Research (2012)
Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas
Authors: Daniel Hübschmann, Kortine Kleinheinz, Rabea Wagener, Stephan H Bernhart, Cristina López, Umut H Toprak, Stephanie Sungalee, Naveed Ishaque, Helene Kretzmer, Markus Kreuz, Sebastian M Waszak, Nagarajan Paramasivam, Ole Ammerpohl, Sietse M Aukema, Renée Beekman, Anke K Bergmann, Matthias Bieg, Hans Binder, Arndt Borkhardt, Christoph Borst, Benedikt Brors, Philipp Bruns, Enrique Carrillo de Santa Pau, Alexander Claviez, Gero Doose, Andrea Haake, Dennis Karsch, Siegfried Haas, Martin-Leo Hansmann, Jessica I Hoell, Volker Hovestadt, Bingding Huang, Michael Hummel, Christina Jäger-Schmidt, Jules N A Kerssemakers, Jan O Korbel, Dieter Kube, Chris Lawerenz, Dido Lenze, Joost H A Martens, German Ott, Bernhard Radlwimmer, Eva Reisinger, Julia Richter, Daniel Rico, Philip Rosenstiel, Andreas Rosenwald, Markus Schillhabel, Stephan Stilgenbauer, Peter F Stadler, José I Martín-Subero, Monika Szczepanowski, Gregor Warsow, Marc A Weniger, Marc Zapatka, Alfonso Valencia, Hendrik G Stunnenberg, Peter Lichter, Peter Möller, Markus Loeffler, Roland Eils, Wolfram Klapper, Steve Hoffmann, Lorenz Trümper, Ralf Küppers, Matthias Schlesner, Reiner Siebert
Journal: Leukemia (2021)

B cells have the unique property to somatically alter their immunoglobulin (IG) genes by V(D)J recombination, somatic hypermutation (SHM) and class-switch recombination (CSR). Aberrant targeting of these mechanisms is implicated in lymphomagenesis, but the mutational processes are poorly understood. By performing whole genome and transcriptome sequencing of 181 germinal center derived B-cell lymphomas (gcBCL) we identified distinct mutational signatures linked to SHM and CSR. We show that not only SHM, but presumably also CSR causes off-target mutations in non-IG genes. Kataegis clusters with high mutational density mainly affected early replicating regions and were enriched for SHM- and CSR-mediated off-target mutations. Moreover, they often co-occurred in loci physically interacting in the nucleus, suggesting that mutation hotspots promote increased mutation targeting of spatially co-localized loci (termed hypermutation by proxy). Only around 1% of somatic small variants were in protein coding sequences, but in about half of the driver genes, a contribution of B-cell specific mutational processes to their mutations was found. The B-cell-specific mutational processes contribute to both lymphoma initiation and intratumoral heterogeneity. Overall, we demonstrate that mutational processes involved in the development of gcBCL are more complex than previously appreciated, and that B cell-specific mutational processes contribute via diverse mechanisms to lymphomagenesis.
Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome
Authors: Simon Kavanagh, Emily Heath, Rose Hurren, Samir H. Barghout, Sanduni U. Liyanage, Thirushi Siriwardena, Jaime Claudio, Tong Zhang, Mahadeo Sukhai, Tracy L. Stockley, Suzanne Kamel-Reid, Amr Rostom, Dina Khalaf, Andrzej Lutynski, Anna Rydlewski, Andre C. Schuh, Vikas Gupta, Hassan Sibai, Dawn Maze, Steven M. Chan, Aaron D. Schimmer
Journal: Blood (2017)
REMOTE PATIENT MONITORING FOR PREDICTING MAJOR ADVERSE CARDIAC EVENTS (MACE) AND CARDIOVASCULAR HOSPITALIZATIONS IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE (SIHD): A REPORT FROM THE PREDICTION, RISK, AND EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS (PRE-MACE) STUDY
Authors: Benita Tjoe, Gillian Gresham, Sandy Joung, Corey Arnold, Shivani Dhawan, Garth Fuller, William Speier, Mitra Mastali, Kelly Mouapi, Irene van den Broek, Janet Wei, Brennan Spiegel, Jennifer Van Eyk, C. Noel Bairey Merz, Chrisandra Shufelt
Journal: Journal of the American College of Cardiology (2021)
THE A BODY SHAPE INDEX AND TYPE 2 DIABETES ARE MUTUALLY INDEPENDENT PREDICTORS OF CARDIOVASCULAR EVENTS AND MORTALITY IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE
Authors: Alexander Vonbank, Barbara Larcher, Arthur Mader, Maximilian Maechler, Lukas Sprenger, Beatrix Mutschlechner, Andreas Leiherer, Daniela Zanolin-Purin, Axel Muendlein, Heinz Drexel, Christoph H. Saely
Journal: Journal of the American College of Cardiology (2021)
THE HEMODYNAMIC GAIN INDEX AND CARDIORESPIRATORY FITNESS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - INSIGHTS FROM RELAX
Authors: Vicente Morales Oyarvide, Donald Richards, Nicholas Hendren, Katherine Michelis, Thanat Chaikijurajai, Siu-Hin Wan, Ambarish Pandey, Mark Drazner, Wai Hong Tang, Justin Grodin
Journal: Journal of the American College of Cardiology (2021)